Regentis Biomaterials (RGNT) director reports fully vested stock option

Rhea-AI Filing Summary

REGENTIS BIOMATERIALS LTD. director Valentine Keith has filed an initial ownership report showing an employee stock option to buy common stock. The option covers 37,500 underlying shares of common stock at an exercise price of $1.46 per share and expires on January 9, 2029. A footnote states that this option grant is fully vested as of the reported date, meaning all 37,500 underlying shares are currently exercisable under the option, although no exercise is reported here.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Valentine Keith

(Last) (First) (Middle)

C/O REGENTIS BIOMATERIALS LTD.

60 MEDINAT HAYEHUDIM

(Street)

HERZLIYA 4676652

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
REGENTIS BIOMATERIALS LTD. [ RGNT ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	(1)	01/09/2029	Common Stock	37,500	$1.46	D

Explanation of Responses:

1. This option grant is fully vested as of this date.

	/s/ Keith Valentine	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What insider position does the Form 3 show for RGNT director Valentine Keith?

The Form 3 shows Valentine Keith holds an employee stock option linked to 37,500 Regentis Biomaterials common shares. This reflects initial reported beneficial ownership through a derivative security rather than direct share holdings.

How many Regentis Biomaterials (RGNT) shares are covered by the reported option?

The reported employee stock option covers 37,500 underlying shares of Regentis Biomaterials common stock. This figure represents the total number of shares that could be acquired upon exercise of the option, subject to its terms and expiration date.

What is the exercise price and expiration date of Valentine Keith’s RGNT option?

The employee stock option has an exercise price of $1.46 per share and expires on January 9, 2029. These terms define the cost and time window for potentially converting the option into common stock.

Is the Regentis Biomaterials stock option held by Valentine Keith fully vested?

Yes, a footnote states that this option grant is fully vested as of the reported date. Full vesting means all 37,500 underlying shares are currently exercisable under the option’s terms, even though no exercise is reported.

Does the Form 3 for RGNT report any stock purchases or sales by Valentine Keith?

No stock purchases or sales are reported. The filing records a holding of an employee stock option as a derivative security, with no buy or sell transactions in the underlying common stock indicated in the provided data.